Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Marker Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Marker Therapeutics, Inc.

MRKR

Marker Therapeutics, Inc.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing non-engineered T cell therapies targeting multiple tumor antigens. Its proprietary MAR-T platform aims to treat hematological malignancies and solid tumors by expanding natural tumor-specific T cells, minimizing tumor escape and adverse effects. The company’s products include autologous and off-the-shelf therapies, with a focus on lymphoma, pancreatic cancer, AML, and MDS, leveraging broad-spectrum, cost-effective immunotherapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Marker Therapeutics, Inc.

1
1
Marker Therapeutics, Inc. Marker Therapeutics Reports $3.2 Million Net Loss in Q1 2026, Improved from $4.4 Million in Q1 2025

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Marker Therapeutics, Inc. Marker Therapeutics Reports 46% Revenue Decline and Ongoing Financial Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Marker Therapeutics, Inc. Marker Therapeutics Reports 36% Revenue Decline in Q3 2025, Net Loss of $2.0 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Marker Therapeutics, Inc. Marker Therapeutics Reports 26% Revenue Decline and Increased Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Marker Therapeutics, Inc. Marker Therapeutics Reports 72% Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Marker Therapeutics, Inc. Marker Therapeutics Reports $6.6M Revenue Growth and Improved Net Loss in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Marker Therapeutics, Inc. Marker Therapeutics Reports Mixed Financial Results, Net Loss Improves in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments